They successfully applied this framework to data regarding LDH and NSE concentrations in patients diagnosed with SCLC and believe that the proposed modelling framework of circulating biomarkers could constitute a powerful additional strategy for disease monitoring in SCLC patients. The gene discussed is ENO2; the disease is small cell lung carcinoma.